Lunit Inc.
Company Snapshot
Founded: 2013
Entity Type: Public
Region: South Korea
Revenue: $19.2 Millions
Revenue Year: 2023
Headquarter: Seoul, South Korea
Key Geographics: North America, Europe, Asia-Pacific
Corporate Address: 4F–9F, 374 Gangnam-daero Gangnam-gu, Seoul Republic of Korea www.lunit.io/en
Company Overview
Lunit develops AI-based solutions for cancer diagnosis and treatment. Lunit’s flagship products include Lunit INSIGHT and Lunit SCOPE. The company offers its products and services through research collaborations with pharmaceutical companies, CROs and diagnostic laboratories such as Guardant Health. Apart from South Korea, the company has offices in China, the Netherlands and the U.S. Investors, including Guardant Health, Fujifilm and Naver, support the company. Lunit products are used by over 2,000 healthcare institutions globally.
Financial Highlights (FY 2023)
Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
Operating Income: ***
This information is available for BCC Research members only.
Lunit Inc. In News
Company's Business Segments
- Cancer Screening : This segment includes Lunit INSIGHT CXR and Lunit INSIGHT MMG.
- Oncology : This segment uses AI-powered software solutions for the entire cancer care continuum, spanning screening, diagnosis, treatment decisions, and drug development.
Applications/End User Industries
- Hospitals and Medical Institutions
- Radiology
- Pathology
- Oncology
- Biopharmaceutical Companies
- Research Institutions
- Public Healthcare/Government Programs
- Medical Device Manufacturing